Stéphanie Philtjens

Stéphanie Philtjens

Auto-generated profile, based on publicly available information

Stéphanie Philtjens

Department of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in The Lancet Neurology
Verified
Journal Article
Closed access
IGIlse Gijselinck
Ilse Gijselinck
TLTim Van Langenhove
Tim Van Langenhove
JZJulie van der Zee
Julie van der Zee
KSKristel Sleegers
Kristel Sleegers
SPStéphanie Philtjens
Stéphanie Philtjens
CBChristine Van Broeckhoven
Christine Van Broeckhoven

30 October 2012 in Human Mutation
Verified
Journal Article
Open access
PDF file
JZJulie van der Zee
Julie van der Zee
IGIlse Gijselinck
Ilse Gijselinck
LDLubina Dillen
Lubina Dillen
TLTim Van Langenhove
Tim Van Langenhove
JTJessie Theuns
Jessie Theuns
OCon behalf of the European Early‐Onset Dementia (EOD) Consortium
on behalf of the European Early‐Onset Dementia (EOD) Consortium
We assessed the geographical distribution of C9orf72 G4C2 expansions in a pan‐European frontotemporal lobar degeneration (FTLD) cohort (n = 1,205), ascertained by the European Early‐Onset Dementia (EOD) consortium. Next, we performed a meta‐analysis of our data and that of other European studies, together 2,668 patients from 15 Western European countries. The frequency of the C9orf72 expansions in Western Europe was 9.98% in overall FTLD, with 18.52% in familial, and 6.26% in sporadic FTLD patients. Outliers were Finland and Sweden with overall frequencies of respectively 29.33% and 20.73%, but also Spain with 25.49%. In contrast, prevalence in Germany was limited to 4.82%. In addition, we studied the role of intermediate repeats (7–24 repeat units), which are strongly correlated with the risk haplotype, on disease and C9orf72 expression. In vitro reporter gene expression studies demonstrated significantly decreased transcriptional activity of C9orf72 with increasing number of normal repeat units, indicating that intermediate repeats might act as predisposing alleles and in favor of the loss‐of‐function disease mechanism. Further, we observed a significantly increased frequency of short indels in the GC‐rich low complexity sequence adjacent to the G4C2 repeat in C9orf72 expansion carriers (P < 0.001) with the most common indel creating one long contiguous imperfect G4C2 repeat, which is likely more prone to replication slippage and pathological expansion.

1 March 2014 in Neurobiology of Aging
Verified
Journal Article
Closed access
ECElise Cuyvers
Elise Cuyvers
KBKarolien Bettens
Karolien Bettens
SPStéphanie Philtjens
Stéphanie Philtjens
TLTim Van Langenhove
Tim Van Langenhove
IGIlse Gijselinck
Ilse Gijselinck
KSKristel Sleegers
Kristel Sleegers

15 December 2015 in Neurology
Verified
Journal Article
Open access
PDF file
IGIlse Gijselinck
Ilse Gijselinck
SMSara Van Mossevelde
Sara Van Mossevelde
JZJulie van der Zee
Julie van der Zee
ASAnne Sieben
Anne Sieben
SPStéphanie Philtjens
Stéphanie Philtjens
ESEric Salmon
Eric Salmon
Objective: To assess the genetic contribution of TBK1, a gene implicated in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and FTD-ALS, in Belgian FTD and ALS patient cohorts containing a significant part of genetically unresolved patients. Methods: We sequenced TBK1 in a hospital-based cohort of 482 unrelated patients with FTD and FTD-ALS and 147 patients with ALS and an extended Belgian FTD-ALS family DR158. We followed up mutation carriers by segregation studies, transcript and protein expression analysis, and immunohistochemistry. Results: We identified 11 patients carrying a loss-of-function (LOF) mutation resulting in an overall mutation frequency of 1.7% (11/629), 1.1% in patients with FTD (5/460), 3.4% in patients with ALS (5/147), and 4.5% in patients with FTD-ALS (1/22). We found 1 LOF mutation, p.Glu643del, in 6 unrelated patients segregating with disease in family DR158. Of 2 mutation carriers, brain and spinal cord was characterized by TDP-43-positive pathology. The LOF mutations including the p.Glu643del mutation led to loss of transcript or protein in blood and brain. Conclusions: TBK1 LOF mutations are the third most frequent cause of clinical FTD in the Belgian clinically based patient cohort, after C9orf72 and GRN, and the second most common cause of clinical ALS after C9orf72. These findings reinforce that FTD and ALS belong to the same disease continuum.

1 March 2013 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
TLTim Van Langenhove
Tim Van Langenhove
JZJulie van der Zee
Julie van der Zee
IGIlse Gijselinck
Ilse Gijselinck
SESebastiaan Engelborghs
Sebastiaan Engelborghs
RVRik Vandenberghe
Rik Vandenberghe
CBChristine Van Broeckhoven
Christine Van Broeckhoven
Frontotemporal lobar degeneration (FTLD) is a collective term for a group of neurodegenerative disorders with predominant atrophy of the frontal and/or the temporal lobes of the brain. Despite similar gross pathologic features, FTLD is markedly heterogeneous in clinical presentation, microscopic characteristics, and underlying genetic causes. Clinically, FTLD presents with either changes in personality and social conduct (behavioral variant frontotemporal dementia [bvFTD]) or with language problems (primary progressive aphasias including semantic dementia [SD] and progressive nonfluent aphasia [PNFA]).1-3 The pathology of FTLD can, in turn, be subdivided according to the identity of the major inclusion protein that is found in protein depositions in degenerating neurons, those being TAR DNA-binding protein 43 (TDP-43; pathologic subclass, FTLD-TDP), tau (FTLD-tau), and FUS (FTLD-FUS).4

11 May 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
BKByungwook Kim
Byungwook Kim
LDLuke Child Dabin
Luke Child Dabin
MTMason Douglas Tate
Mason Douglas Tate
HKHande Karahan
Hande Karahan
ASAhmad Daniel Sharify
Ahmad Daniel Sharify
Jungsu KimJungsu Kim
Jungsu Kim
SPI1 was recently reported as a genetic risk factor for Alzheimer’s disease (AD) in large-scale genome-wide association studies. However, it is unknown whether SPI1 should be downregulated or increased to have therapeutic benefits. To investigate the effect of modulating SPI1 levels on AD pathogenesis, we performed extensive biochemical, histological, and transcriptomic analyses using both Spi1-knockdown and Spi1-overexpression mouse models. Here, we show that the knockdown of Spi1 expression significantly exacerbates insoluble amyloid-β (Aβ) levels, amyloid plaque deposition, and gliosis. Conversely, overexpression of Spi1 significantly ameliorates these phenotypes and dystrophic neurites. Further mechanistic studies using targeted and single-cell transcriptomics approaches demonstrate that altered Spi1 expression modulates several pathways, such as immune response pathways and complement system. Our data suggest that transcriptional reprogramming by targeting transcription factors, like Spi1, might hold promise as a therapeutic strategy. This approach could potentially expand the current landscape of druggable targets for AD.